BRPI0510022A - compostos de tienopiridinona e processos de tratamento - Google Patents
compostos de tienopiridinona e processos de tratamentoInfo
- Publication number
- BRPI0510022A BRPI0510022A BRPI0510022-4A BRPI0510022A BRPI0510022A BR PI0510022 A BRPI0510022 A BR PI0510022A BR PI0510022 A BRPI0510022 A BR PI0510022A BR PI0510022 A BRPI0510022 A BR PI0510022A
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- disease
- treatment
- compounds
- treatment processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010038678 Respiratory depression Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 230000030136 gastric emptying Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000012450 pharmaceutical intermediate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57185204P | 2004-05-17 | 2004-05-17 | |
| US10/955,434 US7488736B2 (en) | 2004-05-17 | 2004-09-30 | Thienopyridinone compounds and methods of treatment |
| PCT/US2005/017121 WO2005121151A2 (en) | 2004-05-17 | 2005-05-16 | Thienopyridinone compounds and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0510022A true BRPI0510022A (pt) | 2007-09-25 |
Family
ID=35310219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510022-4A BRPI0510022A (pt) | 2004-05-17 | 2005-05-16 | compostos de tienopiridinona e processos de tratamento |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7488736B2 (enExample) |
| EP (1) | EP1746994A4 (enExample) |
| JP (1) | JP4897683B2 (enExample) |
| KR (1) | KR101216296B1 (enExample) |
| AU (1) | AU2005252632B2 (enExample) |
| BR (1) | BRPI0510022A (enExample) |
| CA (1) | CA2567268C (enExample) |
| IL (1) | IL178996A0 (enExample) |
| MA (1) | MA28582B1 (enExample) |
| NO (1) | NO20065814L (enExample) |
| RU (1) | RU2006144867A (enExample) |
| WO (1) | WO2005121151A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7968538B2 (en) | 2005-01-25 | 2011-06-28 | Galenea Corp. | Substituted arylamine compounds and methods of treatment |
| WO2007094937A1 (en) * | 2006-02-14 | 2007-08-23 | Exxonmobil Chemical Patents Inc. | A process for manufacturing mcm-22 family molecular sieves |
| EP2445877B1 (en) * | 2008-12-03 | 2014-07-23 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| US8557994B2 (en) * | 2009-07-27 | 2013-10-15 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| JP5676769B2 (ja) | 2010-10-14 | 2015-02-25 | イムナール アクティエボラーグ | Ahr活性化因子としての1,2‐ジヒドロ‐4‐ヒドロキシ‐2‐オキソ‐キノリン‐3‐カルボキシアニリド |
| WO2013009810A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009827A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009812A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc | Methods of treatment |
| KR20220035955A (ko) | 2019-07-22 | 2022-03-22 | 루핀 리미티드 | Sting 작용제로서의 거대고리 화합물 및 이의 방법 및 용도 |
| CN114569566A (zh) * | 2020-12-02 | 2022-06-03 | 四川科瑞德制药股份有限公司 | 一种盐酸米那普仑制剂的制备方法 |
| JP7664491B2 (ja) * | 2022-01-11 | 2025-04-17 | スヴェン・ライフ・サイエンシーズ・リミテッド | 5-HT4受容体アゴニストとしてのピロロ[1,2-b]-2-ピリダジノン化合物 |
| US11725016B1 (en) | 2022-06-02 | 2023-08-15 | Nanopharmaceutics, Inc | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt |
| WO2024253935A1 (en) | 2023-06-05 | 2024-12-12 | Nanopharmaceutics, Inc. | Compositions and methods for oral delivery of sustained release crystalline prx-3140 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3069412A (en) | 1958-08-15 | 1962-12-18 | Fmc Corp | N-aminoazetidine and preparation thereof |
| CA933923A (en) | 1969-12-19 | 1973-09-18 | Eichenberger Kurt | Process for the manufacture of new thiopyranes |
| GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
| DE2925175A1 (de) | 1979-06-22 | 1981-01-08 | Basf Ag | Verfahren zur herstellung von isatosaeureanhydriden |
| IT1203323B (it) | 1987-02-02 | 1989-02-15 | Hoechst Italia Spa | Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
| JP3086295B2 (ja) * | 1990-08-17 | 2000-09-11 | 武田薬品工業株式会社 | チエノピリジン誘導体、その製造法およびacat阻害剤 |
| US5143919A (en) * | 1990-08-17 | 1992-09-01 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives and their pharmaceutical use |
| US5155115A (en) | 1991-03-12 | 1992-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Thienopyridine derivatives |
| US5219864A (en) * | 1991-03-12 | 1993-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Thienopyridine derivatives |
| US5227387A (en) | 1991-09-03 | 1993-07-13 | Dowelanco | Quinoline nematicidal method |
| DE4138820A1 (de) | 1991-11-26 | 1993-05-27 | Basf Ag | Chinolin-3-carbonsaeureamide, deren herstellung und verwendung |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| DE4227747A1 (de) * | 1992-08-21 | 1994-02-24 | Basf Ag | Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| JPH06239858A (ja) | 1993-02-16 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 末梢血管拡張剤 |
| GB9306460D0 (en) | 1993-03-29 | 1993-05-19 | Smithkline Beecham Plc | Novel compounds |
| GB9311562D0 (en) * | 1993-06-04 | 1993-07-21 | Fujisawa Pharmaceutical Co | Heterocyclic derivatives |
| TW449600B (en) * | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| JP3829879B2 (ja) | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| DE19636769A1 (de) | 1996-09-10 | 1998-03-12 | Basf Ag | 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
| DE19724980A1 (de) | 1997-06-13 | 1998-12-17 | Basf Ag | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
| JPH11130777A (ja) | 1997-08-13 | 1999-05-18 | Takeda Chem Ind Ltd | チエノピリジン誘導体、その中間体およびそれらの製造法 |
| US6340759B1 (en) * | 1997-10-02 | 2002-01-22 | Eisai Co., Ltd. | Fused pyridine derivatives |
| AU2879799A (en) * | 1998-02-26 | 1999-09-15 | Neurogen Corporation | 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands |
| DE19815026A1 (de) | 1998-04-03 | 1999-10-07 | Hoechst Schering Agrevo Gmbh | Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| PL204628B1 (pl) | 1998-06-02 | 2010-01-29 | Osi Pharmaceuticals | Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| EP1173168A2 (en) | 1999-04-28 | 2002-01-23 | Respiratorius AB | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| JP3868811B2 (ja) | 1999-10-01 | 2007-01-17 | 大日本住友製薬株式会社 | 新規キナゾリン誘導体 |
| EP1270568A1 (en) | 2001-06-19 | 2003-01-02 | Biofrontera Pharmaceuticals AG | 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist |
| WO2003020728A1 (en) * | 2001-08-30 | 2003-03-13 | Pharmacia & Upjohn Company | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS |
| MXPA03000145A (es) | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| AU2003277215A1 (en) | 2002-10-01 | 2004-04-23 | Predix Pharmaceuticals Holdings, Inc. | Novel neurokinin antagonists and methods of use thereof |
| US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| CN1777612A (zh) | 2003-03-31 | 2006-05-24 | 普雷迪克医药品控股公司 | 新的哌啶基氨基-噻吩并[2,3-d]嘧啶化合物 |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7119205B2 (en) * | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| SI1651234T1 (sl) | 2003-07-25 | 2008-02-29 | Hoffmann La Roche | Kombinacija antagonista mglur2 in inhibitorja ache za zdravljenje akutnih in/ali kronicnih nevroloskih motenj |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| EP2338490A3 (en) | 2003-11-03 | 2012-06-06 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US20060084806A1 (en) | 2004-07-21 | 2006-04-20 | Ramasubramanian Sridharan | Processes for the preparation of imidazo[1,2-a] pyridine derivatives |
| US7407966B2 (en) | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| US7576211B2 (en) | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7968538B2 (en) | 2005-01-25 | 2011-06-28 | Galenea Corp. | Substituted arylamine compounds and methods of treatment |
| AU2006317689B2 (en) | 2005-11-23 | 2013-07-25 | Epix Delaware, Inc. | S1P receptor modulating compounds and use thereof |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| WO2008045558A2 (en) | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Benzothiadiazine compounds and their use |
| AR064245A1 (es) | 2006-11-17 | 2009-03-25 | Epix Delaware Inc | Analogos de adenosina y su uso |
-
2004
- 2004-09-30 US US10/955,434 patent/US7488736B2/en active Active
-
2005
- 2005-05-16 JP JP2007527345A patent/JP4897683B2/ja not_active Expired - Fee Related
- 2005-05-16 RU RU2006144867/04A patent/RU2006144867A/ru not_active Application Discontinuation
- 2005-05-16 CA CA2567268A patent/CA2567268C/en not_active Expired - Lifetime
- 2005-05-16 EP EP05779361A patent/EP1746994A4/en not_active Withdrawn
- 2005-05-16 BR BRPI0510022-4A patent/BRPI0510022A/pt not_active Application Discontinuation
- 2005-05-16 AU AU2005252632A patent/AU2005252632B2/en not_active Ceased
- 2005-05-16 WO PCT/US2005/017121 patent/WO2005121151A2/en not_active Ceased
-
2006
- 2006-11-01 IL IL178996A patent/IL178996A0/en unknown
- 2006-11-13 MA MA29451A patent/MA28582B1/fr unknown
- 2006-11-15 KR KR1020067023904A patent/KR101216296B1/ko not_active Expired - Fee Related
- 2006-12-15 NO NO20065814A patent/NO20065814L/no not_active Application Discontinuation
-
2008
- 2008-12-24 US US12/343,818 patent/US7982040B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050256153A1 (en) | 2005-11-17 |
| JP2007538084A (ja) | 2007-12-27 |
| NO20065814L (no) | 2007-02-12 |
| KR101216296B1 (ko) | 2012-12-28 |
| IL178996A0 (en) | 2007-03-08 |
| US7488736B2 (en) | 2009-02-10 |
| MA28582B1 (fr) | 2007-05-02 |
| US20090163537A1 (en) | 2009-06-25 |
| JP4897683B2 (ja) | 2012-03-14 |
| KR20070047237A (ko) | 2007-05-04 |
| AU2005252632B2 (en) | 2012-03-01 |
| AU2005252632A1 (en) | 2005-12-22 |
| CA2567268C (en) | 2013-07-09 |
| EP1746994A2 (en) | 2007-01-31 |
| WO2005121151A3 (en) | 2006-05-18 |
| RU2006144867A (ru) | 2008-06-27 |
| US7982040B2 (en) | 2011-07-19 |
| EP1746994A4 (en) | 2008-01-23 |
| CA2567268A1 (en) | 2005-12-22 |
| WO2005121151A2 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0510022A (pt) | compostos de tienopiridinona e processos de tratamento | |
| NO20072348L (no) | Thienopyridinone sammensetninger og fremgangsmate for behandling | |
| BRPI0607456A2 (pt) | derivados de oxindol como agonistas do receptor 5ht4 | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| JPH11322711A (ja) | 複素環式カルボキサミド | |
| IL109234A (en) | Indole derivatives, their preparation and pharmaceutical compositions containing them | |
| NZ325914A (en) | Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents | |
| AR041302A1 (es) | Compuestos de imidazopiridina como agonistas del receptor 5- ht4 y composiciones farmaceuticas que comprenden dichos compuestos | |
| TW201004941A (en) | Alpha7 nicotinic acetylcholine receptor inhibitors | |
| EP0773942A1 (en) | 4-indole derivatives as serotonin agonists and antagonists | |
| UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
| WO2004069794A3 (en) | New arylpiperazinyl compounds | |
| EA010891B9 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| CA2559530C (en) | Novel benzyl(idene)-lactam derivatives | |
| ATE449092T1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| JP2008515907A5 (enExample) | ||
| JP6943239B2 (ja) | Kcnq2〜5チャネル活性化剤 | |
| UA87845C2 (ru) | Производные тиенопиридинона и способ лечения расстройств нервной системы | |
| WO2006024955A1 (en) | Azabicyclic amine histamine-3 receptor antagonists | |
| US20050282816A1 (en) | Pyrazinylmethyl lactam derivatives | |
| NO20073732L (no) | Arylpiperazinderivater og anvendelse derav som 5-HT1A-receptorligander | |
| WO2004080407A3 (en) | New serotonin modulating compounds and uses therefor | |
| WO2006106416A1 (en) | PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN | |
| TH77097A (th) | ราพามัยซิน โพลิมอร์พ ll และ การใช้ยา |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NANOTHERAPEUTICS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |